Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer
September 21 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, announced today that it has promoted
Noah Clauser to Chief Financial Officer. Mr. Clauser brings close
to 20 years of financial experience to this role and has been with
Catabasis for 9 years, most recently as Vice President,
Finance.
“Noah has strategically built our financial and operations
functions and has been a valuable team member through a critical
stage for Catabasis,” said Jill C. Milne, Ph.D., Chief Executive
Officer of Catabasis. “We are looking forward to his expanded role
as we approach our potential future transition to a commercial
organization.”
“I am excited for this new opportunity as we approach the next
stage of our company, with top-line results from the Phase 3
PolarisDMD trial for edasalonexent expected in the fourth quarter
of this year,” said Mr. Clauser. “I am looking forward to
continuing our work to make an impact in the lives of patients and
families affected by Duchenne muscular dystrophy.”
Mr. Clauser most recently served as Vice President, Finance at
Catabasis, leading the Company’s finance and operations functions
since August 2017. Previously, he served as Senior Director,
Finance and Controller of the Company from January 2016 to August
2017, and Controller from April 2011 to December 2015. Prior to
joining Catabasis, Mr. Clauser worked at Impress Software, where he
served as Accounting Manager. Mr. Clauser is a licensed CPA in
Massachusetts and holds an M.S. in Accounting and a B.S. in
Management from the University of Massachusetts at Boston.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small
molecule designed to inhibit NF-kB that is being developed as a
potential foundational therapy for all patients affected by DMD,
regardless of their underlying mutation. In DMD the loss of
dystrophin leads to chronic activation of NF-kB, which is a key
driver of skeletal and cardiac muscle disease progression. The
ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy
and safety of edasalonexent for registration purposes.
Edasalonexent is also being evaluated in the GalaxyDMD open-label
extension trial. In the MoveDMD Phase 2 trial and open-label
extension, the Company observed that edasalonexent preserved muscle
function and substantially slowed disease progression compared to
rates of change in a control period, and significantly improved
biomarkers of muscle health and inflammation. The FDA has granted
orphan drug, fast track, and rare pediatric disease designations
and the European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a
summary of clinical results, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company’s global Phase 3 PolarisDMD trial in DMD, the anticipated
timing for top-line results and the Company’s planned transition to
a commercial-stage organization and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” “may” and
similar expressions, constitute forward-looking statements within
the meaning of applicable securities laws and regulations. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: risks and uncertainties: related to the impact
of the COVID-19 pandemic and the effectiveness of the steps we have
implemented to address the pandemic, including the use of
telehealth visits; inherent in the completion of clinical trials
and clinical development; related to whether the results of earlier
stage clinical trials will be predictive of the results of later
stage trials; related to the regulatory review and approval
process; inherent in the commercialization of marketed products;
related to successfully managing the Company’s potential
transformation into a fully integrated company; related to
competitive products, including those already approved and those in
development; inherent in transitioning from a clinical to
commercial supply chain, including the ability to enter into
long-term agreements with key contract manufacturers, overseeing
such manufacturers, and managing inventory, particularly where the
Company expects to use sole source manufacturers for the
foreseeable future; related to the availability of funding
sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements; related to
other matters that could affect the clinical development,
regulatory status, availability or commercial potential of the
Company’s product candidates; and related to general market and
economic conditions and other factors discussed in the “Risk
Factors” section of the Company’s Quarterly Report on Form 10-Q for
the period ended June 30, 2020, which is on file with the
Securities and Exchange Commission, and in other filings that the
Company may make with the Securities and Exchange Commission in the
future. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date of
this press release. The Company anticipates that subsequent events
and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200921005163/en/
Catabasis Investor
relations: Andrea Matthews investors@catabasis.com
Media: Elizabeth Higgins media@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024